Dans le même genre
J&J Completes Its $1 Billion Acquisition of Firefly Bio
CONFIRMÉCONFIANCE 87 %il y a 56 jours"NEW BRUNSWICK, NJ (July 29, 2026) - Johnson & Johnson (NYSE: JNJ[1][3]) today announced the successful completion of its acquisition of Firefly Bio, Inc. ... for $1 billion in cash"; the 8-K furnishing it gives "Date of report (Date of earliest event reported): July 29, 2026".Johnson & Johnson closed its $1 billion cash purchase of Firefly Bio, the South San Francisco biotech behind the Firelink degrader antibody conjugate platform for KRAS-driven and other hard-to-treat solid tumours.$1B0.68J&J Proposes $5.5 Billion Deal to Settle 76,000 Ovarian Cancer Talc Claims
CONFIRMÉCONFIANCE 82 %il y a 58 joursJ&J's release is datelined "New Brunswick, N.J. - JULY 27, 2026 - Johnson & Johnson (NYSE: JNJ[1]) ... today announced", and the copy filed as Exhibit 99.1 to its 8-K is marked "FOR RELEASE AT 6:15PM ET", 22:15 UTC in EDT.Johnson & Johnson announced a proposed resolution of its remaining ovarian talc litigation, about 76,000 claims, with a $5.5 billion commitment paid per claim - no more than $3 billion in 2027 and nothing more before 2028 - if at least 95% of claimants take part.$5.5B0.68DePuy Synthes se sépare de Johnson & Johnson
ESTIMÉCONFIANCE 71 %dans 281 joursLe 10-Q de J&J pour le trimestre clos le 28 juin 2026 vise une « finalisation sous 18 à 24 mois après l'annonce initiale » du 14 octobre 2025 (de la mi-avril à la mi-octobre 2027), et le directeur financier Joseph Wolk a déclaré en juillet que J&J « est en bonne voie pour une séparation à la mi-2027 » (Bloomberg) ; « mi-2027 » est compris comme le milieu de l'année, soit le 1er juillet 2027, qui se situe dans cette fenêtre.[1]L'activité orthopédie de Johnson & Johnson doit quitter le groupe sous le nom de DePuy Synthes – par scission non imposable ou par cession, Apollo étant en discussions autour de 20 milliards de dollars – et J&J affirme être en bonne voie pour une séparation à la mi-2027.0.65J&J Announces Plan to Spin Off DePuy Synthes
Johnson & Johnson World Headquarters, 1 Johnson and Johnson Plaza, New Brunswick, New Jersey 08933, United StatesJohnson & Johnson…
CONFIRMÉCONFIANCE 90 %il y a 344 joursThe release is datelined "NEW BRUNSWICK, NJ, October 14, 2025 - Johnson & Johnson ... today announced the Company's intent to separate its Orthopaedics business"; it states no time of day (CNBC's[3] report was up at 6:29 a.m. EDT and J&J's X post at 6:40 a.m. EDT), so the pin is the all-day 14 October.Johnson & Johnson said it would separate its roughly $9.2 billion-a-year orthopaedics business into a standalone company called DePuy Synthes within 18 to 24 months, and named former Smith & Nephew chief Namal Nawana to run it.0.65J&J Q2 2026 Results: $25.3B Sales, 2026 Outlook Raised
Johnson & Johnson World Headquarters, 1 Johnson and Johnson Plaza, New Brunswick, New Jersey 08933, United States
CONFIRMÉCONFIANCE 83 %il y a 70 joursConfirmed by J&J's release dated "New Brunswick, N.J. (July 15, 2026)", which says it "will conduct a conference call with investors to discuss this earnings release today at 8:30 a.m., Eastern Time" (12:30 UTC; the edited transcript is stamped "JULY 15, 2026 / 12:30PM GMT").[1]Johnson & Johnson reported second-quarter sales of $25.3 billion, up 6.6%, and adjusted EPS of $2.90, and raised its 2026 outlook to about $101.1 billion in sales and $11.68 adjusted EPS at the midpoint.0.64J&J Picks Wilson, North Carolina for a Second 500-Job Drug Plant
CONFIRMÉCONFIANCE 87 %il y a 257 joursThe governor's release is dated "Friday, January 9, 2026" and begins "Today Governor Josh Stein announced Johnson & Johnson ... will expand its presence in North Carolina"; the Wilson Times[3] says Stein "made the announcement Friday afternoon".North Carolina Governor Josh Stein announced that Johnson & Johnson will build a second multibillion-dollar plant in Wilson, a drug product manufacturing facility for cancer and neurology medicines expected to create up to 500 jobs, beside the $2 billion biologics campus it is already building there.0.64J&J Third-Quarter 2026 Results and Investor Call
Johnson & Johnson World Headquarters, 1 Johnson and Johnson Plaza, New Brunswick, New Jersey 08933, United States
PROGRAMMÉCONFIANCE 73 %dans 20 joursScheduled by J&J's 31 August release: it "will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, October 13th to review third-quarter results" and "The press release will be available at approximately 6:45 a.m. (Eastern Time) the morning of the conference call"; 8:30 a.m. EDT is 12:30 UTC.[1]Johnson & Johnson releases its third-quarter 2026 results at about 6:45 a.m. Eastern on Tuesday 13 October and reviews them on an 8:30 a.m. investor call hosted by CEO Joaquin Duato and CFO Joseph Wolk.0.63Apollo in Talks to Buy J&J's DePuy Synthes for About $20 Billion
Johnson & Johnson World Headquarters, 1 Johnson and Johnson Plaza, New Brunswick, New Jersey 08933, United States
CONFIRMÉCONFIANCE 82 %il y a 12 joursThe disclosure is Bloomberg's report, dated "September 11, 2026" (Yahoo's[1][2][5] syndicated copy went up at 22:26 UTC and quotes Friday's closing share prices); Reuters' write-up the same evening says "Bloomberg News reported on Friday", and Quartz's 14 September story is a follow-up, so the pin is the all-day 11 September.Bloomberg reported that Apollo Global Management is in talks to buy DePuy Synthes, J&J's $9.3 billion-a-year orthopaedics unit, at a value close to $20 billion, with a deal possible within weeks though J&J could still spin the unit off instead.$20B0.61FDA Authorizes Abbott's Libre Duo Glucose-Ketone Sensor
CONFIRMÉCONFIANCE 87 %il y a 29 joursThe release is datelined "ABBOTT PARK, Ill., Aug. 25, 2026" and says Abbott "today announced U.S. Food and Drug Administration (FDA[2][3]) authorization of its Libre Duo 10 Day system"; the FDA's De Novo record gives the same decision date, 08/25/2026.The FDA authorized Abbott's Libre Duo 10 Day, the first wearable to continuously track both glucose and ketones, which alerts people with diabetes aged 2 and older to rising ketones before diabetic ketoacidosis.0.59Lilly Agrees to Acquire Centessa for Up to $7.8 Billion
CONFIRMÉCONFIANCE 87 %il y a 176 joursThe joint release is datelined "INDIANAPOLIS and BOSTON and LONDON, March 31, 2026" and says the companies "today announced a definitive agreement for Lilly to acquire Centessa".[1]Lilly agrees to buy Centessa Pharmaceuticals, maker of the orexin agonist cleminorexton for narcolepsy, for $38 a share in cash (about $6.3 billion) plus a CVR worth up to $1.5 billion more; the deal closed on 24 June 2026.$7.8B0.59J&J Enterprise Business Review (Investor Day)
PROGRAMMÉCONFIANCE 85 %dans 76 joursJ&J set the date itself: CFO Joseph Wolk said on the 15 July Q2 call "We look forward to sharing more on strategy, growth catalysts and a longer-term outlook at our Enterprise business review on December 8", and the source[1] reports he "expects to present stronger growth expectations at its Dec. 8 investor day"; no time or venue has been announced, so the pin sits at J&J's headquarters as an all-day date.Johnson & Johnson holds its first enterprise business review since December 2023, where CFO Joseph Wolk says it will set out growth above its 5% to 7% long-term target, with a clear line of sight to double digits by the end of the decade.0.59US and Taiwan Sign a $250 Billion Chip Investment Deal
CONFIRMÉCONFIANCE 86 %il y a 251 joursCNBC[1], published 15 January 2026: 'The U.S. and Taiwan have reached a trade agreement ... the Department of Commerce announced Thursday'; USTR's[2] February fact sheet dates the 'Memorandum of Understanding signed by AIT and TECRO on January 15, 2026'. No signing time is given, so it is an all-day date.A memorandum signed in Washington commits Taiwanese chipmakers such as TSMC to at least $250 billion of new US investment plus $250 billion in Taiwan credit guarantees, in return for a 15% tariff cap and Section 232 chip-tariff exemptions for companies building US fabs.0.59
